According to the recent research report titled ‘Global NASH Market - Analysis By Drug Type, Sales Chanel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)’, available with Market Study Report, global NASH market was remunerated USD 3369.12 million and is anticipated to record a substantial growth during 2021-2026.
 

As per experts, global NASH market growth is primarily driven by launch of pipeline drugs,  increasing technological advancements like special MRI technology MR-EFF (elastography fat fraction) and advanced clinical trials.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3578562/
 

Moreover, rising prevalence of NASH and surging demand for ideal NASH therapeutics are also adding to the market development.
 

Notably, the first-line treatment for patients with non-alcoholic steatohepatitis (NASH) is lifestyle interventions. A liver biopsy will be performed if NASH is suspected wherein a needle is used to extract a small piece of liver tissue, which is then examined under a microscope. This helps the doctor see if there is any scarring or inflammation of the liver tissue.
 

Despite the COVID-19 pandemic significantly impacting worldwide NASH industry dynamics, the business appears to be growing moderately over time. However, major challenges such as R&D progress and funding are expected to be seen in the future.
 

The pandemic could also wreak havoc on the FDA, EMA, and other health agencies, delaying clinical trials and the evaluation and approval of product candidates, including OCA for NASH-related liver fibrosis, thus negatively influencing the business scenario.
 

With respect to sales retail pharmacy segment is predicted to hold major portion of global NASH market share as certain biopharmaceutical manufacturers or businesses sell their products only to a small number of retail pharmacies to have a competitive advantage for these medicines. Apart from this, online provider and hospital pharmacy channels are covered in the report.
 

Elaborating on drug type, the industry is bifurcated into selonsertib & cenicriviroc, elafibranor, ocaliva, and vitamin E & pioglitazone.
 

Regionally, North America, Asia Pacific, Europe, and LAMEA are the key contributors to the overall market growth. Among these, North America held major market share in 2020 with strong impression of Canada on the industry.
 

Leading organizations profiled in global NASH market report are AstraZeneca plc, Genfit SA, Intercept Pharmaceuticals Inc., Zydus Cadila, Novartis AG, 3M Company, Shire plc, Allergan plc (Tobira), Gilead Sciences Inc., and Horizon Therapeutics plc.